Fingerprint
Dive into the research topics of 'A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically